Cargando…
miR-1226-3p Promotes Sorafenib Sensitivity of Hepatocellular Carcinoma via Downregulation of DUSP4 Expression
Background: Sorafenib appears to increase the survival rate of hepatocellular carcinoma (HCC) patients, but its response rate is seriously limited due to drug resistance. Molecular mechanisms underlying sorafenib resistance are still unknown. Herein, we explored the possible role of miR-1226-3p in s...
Autores principales: | Chen, Xianqing, Tan, Wenliang, Li, Wenxin, Li, Wenda, Zhu, Sicong, Zhong, Jinyi, Shang, Changzhen, Chen, Yajin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584923/ https://www.ncbi.nlm.nih.gov/pubmed/31258782 http://dx.doi.org/10.7150/jca.31804 |
Ejemplares similares
-
miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1
por: Tan, Wenliang, et al.
Publicado: (2021) -
TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018) -
Corrigendum to “TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma” [EBioMedicine 40 (2019) 446–456]
por: Tan, Wenliang, et al.
Publicado: (2022) -
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway
por: Tan, Wenliang, et al.
Publicado: (2017) -
Low expression of VSIG4 is associated with poor prognosis in hepatocellular carcinoma patients with hepatitis B infection
por: Zhu, Sicong, et al.
Publicado: (2018)